Bone Mineral Markers in Hypogonadism

Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02062307

Enrollment

Registered

2014-02-13

Start date

2012-08-31

Completion date

2013-08-31

Last updated

2014-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Dysfunction, Hypogonadotropic Hypogonadism, Insulin Resistance

Keywords

Hypogonadism, Asymmetric Dimethyl Arginine, Osteoprotegerin, Fibroblast Growth Factor, Vitamin D

Brief summary

The aim of this study is to investigate the markers of bone mineral metabolism in an unconfounded group of patients with hypogonadism and to search for a relationship between endothelial dysfunction and insulin resistance.

Detailed description

Cardiometabolic disorders are prevalent in patients with hypogonadism. Endothelial dysfunction and insulin resistance are used in determining cardiovascular risk. The role of markers of bone mineral metabolism in hypogonadism is not clearly presented. 49 male patients with hypogonadotropic hypogonadism (HH) and 43 BMI and age matched healthy male subjects were enrolled. Osteoprotegerin (OPG), fibroblast growth factor-23 (FGF-23), vitamin D and asymmetric dimethylarginine (ADMA) levels were measured. The insulin sensitivity was estimated by homeostatic model assessment-insulin resistance (HOMA-IR) formula.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* male patients with hypogonadotropic hypogonadism * being under the age of 45 and over the age of 18 * not previously given testosterone or human chorionic gonadotropin therapy * not have any chronic metabolic disorders or organ dysfunction

Exclusion criteria

* female patients * Other reasons hipogondism * receive any treatment of hypogonadism * presence of comorbid diseases

Design outcomes

Primary

Measure	Time frame	Description
Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 levels	one year	investigate the markers of bone mineral metabolism in patients with hypogonadism

Secondary

Measure	Time frame
relationship between bone mineral metabolism and endothelial dysfunction, insulin resistance	one year

Countries

Turkey (Türkiye)

Outcome results